NDAINTRAVENOUSSOLUTION
Approved
Aug 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 35m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OLINVYK (oliceridine) is an intravenous opioid analgesic approved by the FDA in August 2020 for moderate to severe acute pain management in hospitalized patients. It is a small-molecule mu-opioid receptor agonist designed to provide rapid pain relief in perioperative and acute care settings. The drug represents a newer generation opioid with a focus on IV administration in controlled hospital environments.
Peak5.5 years to LOE
Product is in peak commercial phase post-launch; brand teams are focused on hospital formulary penetration and clinician adoption in the acute care setting.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy
Started May 2016
418 enrolled
Acute Pain
Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty
Started May 2016
407 enrolled
Acute Pain
Career Relevance
OLINVYK career opportunities center on acute care commercialization, hospital formulary management, and payer negotiations. The peak lifecycle stage indicates moderate team expansion potential, with roles focused on clinician adoption and hospital partnerships rather than patient-facing field sales.
Brand Manager
Worked on OLINVYK at Trevena? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.